Rearch homepage new banner Nov 2013

Research

Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination


GLAZgo Discovery Centre: A uniquely close and agile industry-academia collaboration

An IMED Collaboration Update

The GLAZgo Discovery Centre is a unique collaborative venture established by AstraZeneca and the University of Glasgow. Together, we are exploring new pathways for immunological disease processes with the ultimate shared goal of creating better medicines for patients. The Discovery Centre sparks truly innovative thinking by being a melting pot of scientific flair mixed with industry expertise. The agility of the partnership, coupled with the close working relationships between scientists from both sides, is unique among pharma industry collaborations and has the potential to transform the way industry and academia work together.

Download collaboration update (PDF 258kb)

View more collaboration updates
 


Our leaders iconOur leaders

All Directors are collectively responsible for the success of AstraZeneca. Discover general information,  images and biographies of our Board of Directors.

Read more


Pipeline iconOur pipeline

AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.

Read more


Path to meds iconPath to new medicines

The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.

Read more


Neuro iconAZ Neuroscience

Visit our dedicated neuroscience site for more information on our research and partnering in the area.

 

Visit site


Open innovation iconOpen innovation

Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines

Visit site


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Risk_and_reoccurrence_THM 31 August 2015

Early intervention: aiming to avert the consequences of minor stroke and transient ischaemic attacks